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Should cancer survivors fear radiation-induced sarcomas?
MALCOLM FEIGEN
The Radiotherapy Centre, Austin & Repatriation Medical Centre, Victoria, Australia
Abstract
Purpose/Results. Ionizing radiation is carcinogenic and the induction of a second malignancy is a serious potential
long-term complication of radiotherapy. The incidence of radiation-induced sarcomas was evaluated from many large
epidemiological surveys of long-term cancer survivors reported in the literature over the past 30 years and only one case
was found for every 1000 patients irradiated.
Discussion. Although greater numbers of cancer patients are receiving radical radiotherapy and surviving free of disease
for longer intervals, cases of radiation-induced sarcomas are rare and should not deter patients from accepting radiotherapy
as treatment for curable cancers. With improvements in the administration of radiotherapy over the past two decades
which are resulting in less damage to bone and soft tissues, it is likely that fewer cases of this condition will be seen in
the future. If these sarcomas are diagnosed early, long-term survival can be achieved with surgical excision and possibly
re-irradiation, as occurs in other types of sarcomas.
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Introduction
Advances in cancer treatments are producing in-
creasing numbers of healthy long-term survivors
and, as a consequence, the delayed complications of
anti-cancer therapies are assuming a greater
signi® cance. Radiation has been recognized both as
a therapeutic agent capable of curing localized ma-
lignancies and as a mutagen which may induce new
cancers. It is just under 100 years since the ® rst
cases of radiation-induced tumours were recog-
nized, in the ® rst decade following the discovery of
X-rays by Ro È ntgen in 1895, when pioneer radio-
graphers were reported with squamous cell car-
cinomas on exposed hands
1 and with leukaemias. A
soft tissue sarcoma induced by radiation was de-
scribed in 1904 by Perthes
2 and, in the 1920s, bone
sarcomas were noted following irradiation for tuber-
culous arthritis and radium exposure of workers
painting watch dials.
3,4 Cancer patients may develop
second neoplasms spontaneously or as a conse-
quence of the same genetic or environmental factors
which led to the development of their ® rst tumour,
and the role of radiation can be dif® cult to establish
since no speci® c histological or biochemical markers
have yet been identi® ed. However, speci® c cases
may be attributed to radiotherapy when they de-
velop in normal tissues that have been previously
irradiated, following a reasonable induction interval,
particularly if the histology is unlike the usual
tumours of the region.
Sarcomas can be categorized as radiation induced
if they meet the following criteria, adapted from the
original prerequisites established by Cahan et al.:
5
(1) the sarcoma must develop within the
boundaries of a previously irradiated area;
(2) a relatively long asymptomatic latent period (at
least 4 years) must have elapsed;
(3) the sarcoma must have a different histology
from the original lesion;
(4) the sarcoma must be histologically con® rmed.
Bone and soft tissue sarcomas induced by thera-
peutic irradiation are frequently advanced by the
time they are diagnosed and are usually incurable.
With current trends to use megavoltage radiother-
apy for organ conservation as an alternative to
surgery, often in combination with intensive chemo-
therapy protocols, in growing numbers of cancer
patients, it is important to establish how commonly
these cases occur and ® nd ways to diagnose them
early when they are amenable to the curative treat-
ments that are applied for primary sarcomas. The
literature was reviewed to de® ne the incidence of
cases of bone and soft tissue sarcomas which have
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developed within radiation ® elds of patients who
were treated by radiotherapy and survived beyond
a reasonable latent period to allow time for the
development of a radiation-induced sarcoma.
Discussion
Radiation-induced sarcomas
A literature review of 344 sarcomas following ir-
radiation undertaken by Robinson and colleagues
6
in 1988 found that the median latent interval was 11
years and the median survival was 12 months, with
only 11% of patients alive after 5 years. Most pa-
tients were diagnosed at an advanced stage with
sarcomas that were high grade and usually unre-
sectable, often developing metastases and unrespon-
sive to chemotherapy. Histologically, the largest
group comprised osteosarcomas, followed by
® brosarcomas, malignant ® brous histiocytomas,
angiosarcomas, chondrosarcomas and others. The
commonest primary was breast cancer, then
gynaecological cancers and retinoblastoma.
The range of radiation doses found to induce
sarcomas is wide and tends to be higher for mega-
voltage than orthovoltage (DXR) treatments. These
modalities have different photon absorption patterns
which have led to the phasing out of orthovoltage
radiotherapy for the majority of cancer patients over
the past 40 years. Bone tumours and sarcomas in
cutaneous and subcutaneous tissues are more com-
mon after orthovoltage therapy,
7 which delivers to
bone approximately twice the dose that is absorbed
by adjacent soft tissues. Some reviews have noted a
dose± response relationship for radiation doses in
excess of 10 Gy,
8,9 below which very few cases of
radiation-induced sarcomas have been reported. It
has not been established whether children are at
higher risks than adults, allowing for the longer time
interval for them to develop sarcomas.
10
Population-based studies of radiation-induced
sarcomas have uniformly found very low incidence
rates. Figures reported from large cancer centres
range from 0.03% and 0.38% of all 5-year sur-
vivors
8,11,12 to 0.27% of all 10-year survivors.
13 Be-
tween 1% and 3% of all sarcomas have been
associated with prior irradiation to the sarcoma site,
and soft tissue sarcomas are three times as common
as bone sarcomas.
7,14,15
A number of familial conditions have been linked
to multiple cancers including sarcomas, and it is
likely that radiation will increase the incidence of
sarcomas occurring in these patients. This has been
long appreciated in retinoblastoma patients,
16 where
the genetic cases with bilateral tumours have a high
rate of sarcomas within the radiation port as well as
at more peripheral sites. Neuro® bromatosis
17 and
the Li-Fraumeni syndrome
18 are two other autoso-
mal dominant genetic conditions where sarcomas
may develop in the absence of radiotherapy, and the
sarcoma classi® ed as radiation induced when this is
but a secondary factor.
Other factors which have been associated with the
development of sarcomas in large numbers of case
reports include excessive radiation damage to skin,
bone and soft tissue, and the contributory effects of
chemotherapy. The majority of cases have been
reported following orthovoltage radiotherapy, where
frequently higher daily dose fractions were given
than is acceptable in current radiotherapy practice.
Patients were often exposed to multiple courses of
radiotherapy to the sarcoma site and total doses
were commonly far in excess of what is now re-
garded as the radiation tolerance dose for the tissue.
It is probable that some chemotherapy regimens
stimulate sarcoma induction,
19± 21 and in children at
least, alkylating agents may double the risk.
9 For
many cancers the total doses of adjuvant chemo-
therapy have been reduced in recent years following
evidence that less intensive regimens are equally
effective.
Retinoblastomas
Retinoblastoma is a cancer affecting young children
which can be cured by radiotherapy. Inherited in
around 40% of cases, genetic cases are usually bilat-
eral and follow an autosomal dominant pattern of
inheritance. There is a strong association with sarco-
mas, which occur both within radiation portals and
at other sites, frequently in patients who have not
been given radiotherapy.
The largest study of 1603 long-term retinoblas-
toma survivors from New York and Boston hospitals
treated from 1914 to 1984 by Eng and colleagues
22
found that 6.6% died from second tumours after a
median follow-up of 17 years from radiotherapy,
resulting in a cumulative probability of death from
second primary neoplasms of 26% at 40 years fol-
lowing diagnosis for patients with bilateral disease.
However, this report included cases other than
sarcomas, and an unspeci® ed number occurred
outside the ® eld of irradiation. Second tumours are
not always fatal, and many are cured by aggressive
treatment.
23
Radiotherapy has a well-established role in the
treatment of retinoblastomas, curing early cases with
the preservation of useful vision. Bone and soft
tissue sarcomas may develop irrespective of whether
the patient has received radiotherapy or not, and the
recommended optimal radiation dose is now half
that previously given. As a further bene® t, it has
been noted that prophylactic retinal radiotherapy
can signi® cantly reduce the incidence of contralat-
eral retinoblastomas in familial cases, using a radio-
therapy technique where the exit dose passes
through the clinically unaffected eye.
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Table 1. Breast cancer: radiation-induced sarcomas following radiotherapy
No. of
sarcomas
No. of Follow-up Relative Incidence
Cohort patients (years) Bone ST risk (%) Reference
San Francisco, University of California 445 5.0 1 0 Ð 0.22
11
1928± 1958
Boston, MA General Hospital 2 250 10.0 4 1 Ð 0.22
25
1953± 1968
Toronto, Princess Margaret Hospital 16 000 5.0 4 0 Ð 0.05
8
1958± 1978
University of Chicago 221 8± 42 2 4 6.0 2.71
26
1927± 1970
Oslo, Norwegian Radium Hospital 2 764 10.0 2 1 Ð 0.27
13
1961± 1971
Marseille Cancer Institute* 2 280 7.9 0 2 3.4 0.02
27
1960± 1981
Duke University Medical Centre 140 6.3 0 0 Ð 0.00
28
1970± 1981
Villejuif, Institut Gustav Roussy 7 620 7.2 3 6** 1.81 0.12
29
1954± 1983
Boston, Joint Center Radiation Therapy* 1 624 6.5 2 1 Ð 0.18
30
1968± 1985
Edinburgh, Western General Hospital 3 199 . 18 4 1 7.3 (bone) 0.26
31
1954± 1964 NS (ST)
Milan, Istituto Tumori* 3 295 7.5 0 3 15.8 0.09
32
1973± 1989
West Sweden 13 490 8.4 0 12 2.2 0.09
33
1960± 1980
* Breast conservation series.
**Excludes arm angiosarcomas (Stewart± Treves) syndrome.
NS 5 not signi® cant; ST 5 soft tissue.
Breast cancer
Many cancer centres and registries have reported
radiation-induced sarcomas in long-term survivors
of breast cancer treated with radiotherapy,
8,11,13,25± 33
and these are summarized in Table 1, which in-
cludes over 50 000 patients treated over the past 70
years with median follow-up of at least 5 years. The
overall incidence for radiation-induced sarcomas
was 0.10% (53/53 328). Most bone sarcomas arose
in the scapula, humerus, clavicle or ribs and were
osteosarcomas, and the majority were incurable.
34
Incidences were higher in series using orthovoltage
radiotherapy than in later studies using megavoltage
irradiation and, in the recent reports, soft tissue
sarcomas outnumbered bone sarcomas. The highest
incidence reported in a recent series was 1.10%,
from 1382 consecutive autopsies on women dying
with breast cancer (Roswell Park 1956± 1988), but
this is not comparable to the other reports because
of selection factors.
35
The large Swedish registry study of Karlsson
et al.
33 reviewed in detail all cases of soft tissue
sarcomas in 13 490 women treated for breast cancer
over a 20-year period and found the mean annual
incidence of soft tissue sarcomas was doubled to
0.02% compared to the normal population. One-
third of their 18 cases had not received radiotherapy
to the sarcoma site and, using a case-control
analysis, half the radiation-induced sarcomas were
found to have lymphoedema and/or high radiation
doses as predisposing factors. The very low risk of
sarcoma development, it was concluded, was likely
to be even lower with the reduction in the dose and
volume of breast irradiation and rarity of
lymphoedema using the combined techniques of
radiotherapy and surgery now widely adopted. Cur-
rent standard practice consists of tangential beam
irradiation with computer-assisted planning and it is
uncommon to irradiate the axilla or supraclavicular
fossa. Dose fractionation protocols have evolved to
ensure good cosmesis is a major objective and bone
and soft tissue complications are now rare, particu-
larly at ® eld junctions, which were a common site
for sarcomas to arise.
29,30,36
Many recent reports have described sarcomas
arising in conserved breasts following the increased
use of lumpectomy and breast irradiation as an
alternative to mastectomy. The potential risk of
radiation-induced sarcomas has been a controversial
issue, and three cases have been reported in over8 M. Feigen
3000 patients followed prospectively since 1973,
from the Milan Cancer Institute, the centre which
reported the ® rst randomized trial in breast con-
servation. Only one of the three cases was fatal. The
rarity of these cases was such that no change in
the current policy of conservative therapy with
radiotherapy for breast cancer was advocated.
32
Angiosarcomas of the breast or overlying skin are
now the most common sarcoma following breast
conservation treatment,
37 and have a better prog-
nosis than the other types of sarcoma, with most
cases cured by mastectomy, particularly if they are
diagnosed early. Malignant ® brous histiocytomas
and ® brosarcomas have also been reported.
38
Many case reports describe sarcomas which arose
in areas of chronic radiation damage from excessive
doses of orthovoltage radiotherapy, at junctions of
adjacent radiation ® elds or at hot spots when cur-
rent methods of computerized planning with tissue
density corrections were not available. It is highly
likely that such cases do not occur with modern
radiotherapy practice, where a great deal of care is
taken to avoid poor cosmetic results when breast
conservation techniques for early cases of breast
cancer are utilized as an alternative to mastectomy.
The common sites of bone sarcomas, the scapula,
humerus and clavicle, are usually omitted from
current radiotherapy techniques, which do not
routinely treat nodal regions.
Hodgkin’s disease
Patients with Hodgkin’s disease are usually young
and the vast majority are cured by radiotherapy
and/or chemotherapy with few complications.
MOPP (mustine, vincristine, procarbazine, pred-
nisone) chemotherapy may induce acute non-
lymphocytic leukaemia in the ® rst decade of follow-
up, but thereafter a growing number of patients are
at risk of developing solid tumours, a small pro-
portion of which are sarcomas induced by their
therapeutic irradiation. Many cancer centres have
reviewed their long-term survivors to report increas-
ing rates of second malignancies with longer periods
of follow-up, and collaborative groups have com-
bined national and international cohorts of patients
to assess the risks of sarcoma development, as de-
tailed in Table 2. In 15 studies which followed a
total of 69 000 patients with Hodgkin’s disease
treated since 1943, only 0.14% developed sarcomas
following radiotherapy.
39± 53 However, some reports
do not provide suf® cient details to determine
whether all their cases would qualify as radiation-
induced sarcomas. The most consistently reported
solid tumours found following radiotherapy are
non-Hodgkin’s lymphoma, breast cancer and lung
cancer.
Factors other than radiotherapy which are poten-
tially related to the induction of these second malig-
nancies include chemotherapy, which was given to
the majority of patients, immunological abnormali-
ties and a genetic predisposition, while other cases
may be coincidental and found through the closer
medical surveillance that occurs in young cancer
survivors.
Testicular tumours
Testicular cancers, like Hodgkin’s disease, generally
affect young adults and have cure rates exceeding
90%, with seminomas commonly treated by ir-
radiation and teratomas usually receiving chemo-
therapy following orchidectomy. Many cancer
institutions, national cancer registries and inter-
national cooperative groups have reviewed their
long-term testicular cancer survivors and reported
on second malignancies, and the larger studies are
detailed in Table 3.
10,39,54± 62 Some increases in the
incidence of lung, gastrointestinal and genitourinary
cancers have been found, but no study has found a
signi® cant risk of bone sarcomas, and the relative
risk for soft tissue sarcomas varies from 1.0 to 5.4.
59
Of the 50 000 patients listed in the table, followed
for a median duration of 5± 15 years, 0.05% devel-
oped a subsequent sarcoma, and this ® gure includes
some cases which may not have received radiother-
apy or developed the sarcoma in tissues outside the
radiation ® eld.
Modi® cations to the treatment of testicular
tumours in recent years include signi® cant reduc-
tions in the dose and volume of radiotherapy, the
omission of routine irradiation to the mediastinum,
and the increasing use of surveillance and chemo-
therapy without irradiation, particularly in non-
seminomas.
57 The addition of chemotherapy has
been associated with some of the reported sarcomas,
and there is a risk of acute leukaemia and bladder
cancer following some cytotoxic regimes.
63 Com-
bined treatment with radiotherapy and chemo-
therapy is rarely practised, unlike the situation with
Hodgkin’s disease where cure rates may be im-
proved with optimum use of both modalities. Low-
dose radiotherapy (16± 20 Gy) is recommended for
in situ carcinoma of the contralateral testis after
positive biopsies, and can prevent the development
of invasive germ cell tumours,
64 demonstrating the
general acceptance that the bene® ts of irradiation far
outweigh any risk of radiation-induced cancer.
Risk factors other than radiation have been
identi® ed in some case reports of radiation-induced
sarcomas in testicular cancer patients, and it has
been postulated that some teratomas transform into
sarcomas spontaneously.
65,66 Both radiation and
chemotherapy can produce differentiation of
immature or undifferentiated teratomas.
Brain tumours
Radiotherapy has been used in the treatment of
benign brain tumours in large numbers of patientsRadiation-induced sarcomas 9
Table 2. Hodgkin’s disease: sarcomas following radiotherapy
No. of Relative
sarcomas risk
No. of Follow-up
Cohort patients (years) Bone ST Bone ST Comments Reference
International Agency 28 462* 4.1 5 4 NS NS Sarcoma sites
39
for Research on not identi® ed
Cancer
1945± 1984
Seven published studies 6 513 5.4 4 11 10.0 10.0 Sarcoma sites
40
1964± 1981 not identi® ed
Italian centres 496 10.5 0 2 NS NS Sarcoma sites
41
1969± 1979 not identi® ed
International Database 12 411* 6.7 6 4 6.2 NS Sarcoma sites
42
on Hodgkin’s Disease not identi® ed
1960± 1987
British National 1 859 6.5 2 0 15.0 NS Sarcoma sites
43
Lymphoma Investigation not identi® ed
1970± 1987
Houston, MD Anderson 1 013* . 5.0 2 2 NS NS Sarcoma sites
44
Hospital not identi® ed
1966± 1987
Norwegian Radium 839 9.0 0 0 NS NS One sarcoma
45
Hospital outside
1968± 1988 radiation port
Florence, Italy 1 121* . 5.0 0 3 NS NS Sarcoma sites
46
1960± 1988 not identi® ed
Netherlands centres 1 761 9.2 0 3 NS 8.8 All in
47
1966± 1986 radiation ports
North American centres 9 280* 7.1 24 0.9 Sarcoma sites
48
1940± 1987 not identi® ed
Australasian Patterns of 820 10.0 2 NS NS Sarcoma sites
49
Care not identi® ed
1969± 1988
Boston, JCRT 794 11.0 6 NS NS Sarcoma sites
50
1969± 1988 not identi® ed
St Jude Children’s 469 9.0 4 2 NS NS Sarcoma sites
51
Research Hospital not identi® ed
1962± 1993
Late Effects Study Group 1 270 11.4 4 2 24.6 NS Sarcoma sites
52
1955± 1986 not identi® ed
Nordic countries 1 641* 10.4 1 1 NS NS One more
53
1943± 1987 sarcoma outside
radiation port
*Includes cases treated with chemotherapy alone.
who subsequently live out their full life span. Cases
of radiation-induced sarcomas are rare and only 29
case reports of ® brosarcomas in the region of the
pituitary fossa have been collected over the past 30
years in a literature review of irradiated pitui-
tary tumours,
67 from an unknown patient denomi-
nator, often after excessively high doses. Only one
sarcoma has been reported in ® ve recent series of
1510 irradiated pituitary adenomas (0.07%) de-
tailed in Table 4.
67± 71 Some 47 cases of post-ir-
radiation gliomas have also been reported,
69 but
these too are rare and may be diminishing in fre-
quency with modern radiotherapy techniques and
equipment.
Head and neck cancers
Excluding retinoblastomas, the risk of sarcomas fol-
lowing therapeutic irradiation in head and neck
cancers is very low. In the 10 reports totalling
14 000 patients, summarized in Table 5,
12,72± 80 the
incidence was 0.16%. This is consistent with the
one case of radiation-induced sarcoma for every
1250 treated patients estimated by Parsons in a10 M. Feigen
Table 3. Testicular cancers: sarcomas following radiotherapy
No. of Relative
sarcomas risk
No. of Follow-up
Cohort patients (years) Bone ST Bone ST Comments Reference
Princess Margaret 652 9.1 1 0 NS NS Incidence
10
Hospital, Toronto 0.15%
Scotland 547 15.4 0 0 NS NS One
54
1950± 1969 sarcoma was
outside the
radiation
portal
International Agency for 17 730 6.4 1 7 NS 3.0 Sarcoma sites
39
Research on Cancer not identi® ed
1945± 1984
South Thames Cancer 1 004 6.8 Ð Ð NS NS Ð
55
Registry
1961± 1980
Norwegian Radium 876 12.7 Ð Ð NS NS Ð
56
Hospital
1956± 1977
USA Patterns of Care 387 17.0 0 0 NS NS Ð
57
1973± 1974
Danish Cancer Registry 16 187 9.5 0 7 NS 2.4 All sites
58
1943± 1987 irradiated
Netherlands Cancer 1 909 7.7 1 2 NS 5.4 Sarcoma sites
59
Registry not identi® ed
1971± 1985
Hannover 1 025 5.1 0 0 NS NS One sarcoma
60
1970± 1990 occurred after
chemotherapy
Berlin 584 6.0 0 0 NS NS Ð
61
1969± 1992
SEER Program, 9 739 7.0 0 6 NS 3.6 Sarcoma sites
62
Connecticut Registry not identi® ed
1935± 1991
Table 4. Pituitary adenomas: second malignancies following radiotherapy
No. of Follow-up No. of Other Relative
Cohort patients (years) sarcomas tumours risk Reference
London, St Barts Hospital 332 11.0 0 Glioma (2) NS
67
1961± 1982 Neuroblastoma (1)
London, Royal Marsden 334 11.0 Meningeal Glioma (1) 9.4
68
Hospital sarcoma (1) Meningioma (2)
1962± 1986
Toronto, Princess Margaret 305 7.9 0 Glioma (4) 16
69
Hospital
1972± 1986
Queensland Radium Institute 268 12.8 0 Ð NS
70
1962± 1986
Edinburgh, Western General 271 8.0 0 Lymphoma (1) NS
71
Hospital
1962± 1990
standard reference book,
81 assuming a 40% long-
term survival rate. The most common second malig-
nancies in patients irradiated for head and neck
cancers are new carcinomas in the head and neck
region, and lung and oesophageal carcinomas re-
lated to chronic exposure to the carcinogens of
tobacco smoke and alcohol, compared to which
radiation is a minor irritant.
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Table 5. Head and neck cancers: radiation-induced sarcomas
No. of sarcomas
No. of Follow-up
Cohort patients (years) Bone ST Comments Reference
Philadelphia, Fox Chase Center 611 . 5.0 1 Incidence 0.16%
72
1929± 1973
Toronto, Princess Margaret Hospital 1 600 . 5.0 0 0 Ð
73
1958± 1974
Paris, Curie Institute 1 000 . 5.0 1 2 Incidence 0.30%
74
1957± 1980
Tokyo Medical and Dental University 1 429 4.6 0 1 Incidence 0.07%
75
1954± 1985
Los Angeles, University of California 2 151 5± 30 0 0 Ð
76
1955± 1979
University of Rochester 235 10.0 0 0 Ð
77
1957± 1983
Netherlands Cancer Institute 2 500 2± 17 0 5 Incidence 0.20%
78
1977± 1993
University of Florida 490 2± 32 0 0 Ð
79
1964± 1991
National Taiwan University Hospital 2 112 . 5.0 8 0 Incidence 0.38%
12
1974± 1988
Chang Gung Hospital, Taipei 1 562 4.6 0 4 Incidence 0.25%
80
1979± 1993
Table 6. Cervical cancer: sarcomas following radiotherapy
No. of Relative
sarcomas risk
No. of Follow-up
Cohort patients (years) Bone ST Bone ST Comments Reference
Warsaw, Institute of Oncology 8 043 8.6 0 6 NS 2.9 Incidence 0.07%
83
1948± 1966 (radiation
induced)
International Radiation 82 616 7.6 11 27 NS 1.9 Sarcoma sites
82
Study of Cervical Cancer not identi® ed
1960± 1984
Danish Cancer Registry 20 727 10.1 5 26 NS 1.5 Eleven cases in
84
1943± 1982 irradiated sites
Japanese institutions 7 694 7.1 0 2 NS NS Both cases in
85
1961± 1981 uterus
International Cancer 49 828 10.7 17 33 3.0 2.1 Sarcoma sites
86
Registries Study not identi® ed
1935± 1990
Carcinoma of cervix
Endocavitary and external beam radiotherapy have
long been established as a standard method of treat-
ing cervical cancer. In 1985, an international collab-
oration involving 15 cancer registries in Europe and
North America reported on the numbers of second
cancers among a huge cohort of 182 000 women
treated for cervical cancer, comparing those treated
by radiotherapy and by surgery alone.
82 Connective
tissue tumours were slightly increased in the irradi-
ated group (relative risk 2.3 after 10 years), as were
some other malignancies, including carcinomas of
the bladder, rectum and other genital organs in
heavily irradiated tissues, but not bone tumours.
Sarcoma sites were not identi® ed and the number
occurring away from the radiation port was not
stated. Overall, the number of cancers which could
be attributed to irradiation was estimated to be at
most 5%, and this was more than counterbalanced
by the reduction in the incidence of breast cancer,
probably secondary to ovarian ablation. Three of
four smaller studies showed similar trends.
83± 86
Table 6 shows the reported cases of sarcomas in
170 000 long-term survivors of radiotherapy, for an
overall incidence of 0.08%.12 M. Feigen
In a follow-up study from the International Radi-
ation Study of Cervical Cancer, Boice et al. analyzed
38 sarcomas according to site using case-matched
controls and found no signi® cant increase in the risk
for bone sarcomas but some increased risk for soft
tissue sarcomas (both relative risks 1.9) which oc-
curred within the irradiated region.
87 The risk of
pelvic soft tissue sarcomas was doubled following
cervical radiotherapy. Despite many anecdotal
reports of uterine tumours including sarcomas
occurring after radiotherapy,
88,89 a strong body
of epidemiological literature has not identi® ed
a de® nite relationship between radiotherapy and
sarcomas arising from the uterus.
90
Conclusions
Radiotherapy has an established place in the treat-
ment of a wide range of neoplastic conditions, and
the proportion of cured patients continues to grow.
Virtually all will enjoy a further 10 years of life before
they approach the time at which any sarcoma in-
duced by their earlier therapy could appear.
Despite numerous anecdotal reports of sarcomas
arising in cancer patients who have received radio-
therapy, large epidemiological studies involving hun-
dreds of thousands of radiotherapy patients have
shown that at most only 5% of all second primary
cancers can be convincingly linked to the radiation
treatment,
91 and all the others are attributable to
life-style, inheritance and other carcinogens. Of the
360 000 radiotherapy patients evaluated in the re-
ports in this review, only 0.1% or one patient in a
thousand has subsequently developed sarcomas
which meet the criteria of being radiation induced.
The risk of sarcoma development following
irradiation is extremely low and should be weighed
against the risks of death and carcinogenicity from
hormonal anti-cancer agents (e.g. cardiovascular
toxicity and vaginal adenocarcinoma from stil-
boestrol, breast cancer from oestrogens, endometrial
cancer from tamoxifen) or chemotherapeutic drugs
(e.g. leukaemia from alkylating agents and
etoposide, bladder cancer and possibly sarcoma
from cyclophosphamide
92), or the operative morbid-
ity and mortality of surgery, all alternatives to radio-
therapy in the treatment of cancer patients.
15
Potential carcinogenicity should not be regarded as
a contraindication to the use of radiotherapy, even
in patients with retinoblastoma and neuro-
® bromatosis where a higher risk of tumour induc-
tion is recognized. In the more common cancers as
well, the long-term bene® t derived from radiother-
apy far outweighs the serious side-effects, provided
standard techniques are used.
Radiation-induced sarcomas often arise in areas
heavily damaged by radiation doses far in excess of
normal tissue tolerance and they are likely to be seen
even less frequently with current standards of treat-
ment which use lower doses of megavoltage ir-
radiation delivered in daily fractions of 2 Gy, avoid
multiple courses of treatment and utilize planning
by modern computer-assisted techniques, resulting
in acceptable acute toxicity and infrequent chronic
bone and soft tissue complications. Another much-
feared potential complication, the anaplastic trans-
formation of benign or low-grade tumours following
irradiation, occurs even less frequently than radi-
ation-induced sarcomas, and cases identical to those
anecdotally attributed to irradiation have also been
found following other types of treatment in the
absence of radiotherapy.
93± 95
There is evidence in recent reports of radiation-
induced sarcomas that aggressive management with
early diagnosis and complete local resection results
in prolonged survival no different from sarcomas
unrelated to prior irradiation, particularly if they
develop in soft tissue rather than bone.
23,30,36± 38,96
Regular follow-up examinations of cancer patients
at the centre where their treatment took place
should promote early detection by prompt investiga-
tion of any new masses, with biopsies to exclude the
alternative diagnosis of relapse from the original
cancer which commonly delays optimal sarcoma
treatment. Complete excisions should be performed
and consideration given to post-operative re-ir-
radiation as occurs for primary soft tissue sarcomas.
A role for chemotherapy in treatment is yet to be
established, and some agents may increase the inci-
dence of these rare tumours.
21,91
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